Cardinal Health Inc. ($CAH) Stock Forecast: Up 9.4% Today

What is Cardinal Health Inc.?

Cardinal Health (CAH) is a prominent domestic pharmaceutical wholesaler with a significant market share in the US drug distribution sector. Today, the stock experienced a strong bullish movement.

Why is Cardinal Health Inc. going up?

CAH stock is up 9.4% on Feb 5, 2026 20:03

• Cardinal Health's robust growth momentum, driven by strong utilization and successful acquisitions, has led to an impressive earnings report that surpassed analyst expectations.
• The company's consistent guidance hikes and increased fiscal-year earnings guidance have instilled confidence in investors, resulting in a surge in the stock price.
• Cardinal Health's focus on strategic initiatives and solid financial performance, including a significant increase in sales and adjusted earnings, has propelled the stock to reach a new 52-week high.
• The positive market sentiment towards Cardinal Health is further fueled by the CEO's explanation of the factors contributing to the company's success, reinforcing investor optimism in the stock's future prospects.

CAH Price Chart

CAH Technical Analysis

CAH News

Cardinal's Growth Engine Fires Across the Portfolio From Utilization Strength and New Acquisitions

Cardinal Health's growth is being driven by strong utilization and new acquisitions across its portfolio. The company, one of the three leading domestic pharmaceutical wholesalers, reported strong growth momentum, leading to another estimate beat and a guidance hike for fiscal 2025. With annual US drug distribution sales exceeding $200 billion, Cardinal Health supplies roughly one-fourth of the overall market.

https://www.morningstar.com/company-reports/1424742-cardinals-growth-engine-fires-across-the-portfolio-from-utilization-strength-and-new-acquisitions

Cardinal Health Stock Jumps After Earnings. Its CEO Explains What Went Right.

Cardinal Health reported fiscal second-quarter earnings that exceeded analyst expectations, leading to a jump in its stock price. The company also announced an increase in its fiscal-year earnings guidance for the second time. This positive performance has prompted the CEO to explain the factors contributing to their success.

https://www.barrons.com/articles/cardinal-earnings-stock-price-ceo-360b636e?gaa_at=eafs&gaa_n=AWEtsqcKKBq7CZqZx-bdOmKYbmQytxNeUzGKg7HTnFKWlG4BTY9D-vKWuKmu&gaa_ts=6984dcd8&gaa_sig=036pk3PBExUG9kiILmXT09Dm_vDzewTwnAlS44W9SxxbCsBFe6jlPMWXFfKzKSKzO6nZg64b4bZOZxQg64GWHg%3D%3D

McKesson’s Strong Quarter Highlights Shift Toward Post Separation Focus

McKesson (NYSE:MCK) reported strong fiscal third-quarter results, driven by momentum in oncology, biopharma services, and pharmaceutical distribution. The company is progressing with the planned IPO of its medical surgical business by the second half of 2027, which will enable McKesson to focus on its core drug distribution and services. This strategic shift and solid financial performance, including raised full-year EPS guidance, reflect the company's evolving business model and potential for future growth in specialty pharmaceuticals.

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckessons-strong-quarter-highlights-shift-toward-post-separa

Cardinal Health Stock Roars Higher. Another Guidance Boost Can Do That.

Cardinal Health (CAH) reported fiscal second-quarter earnings that exceeded analyst expectations, leading the company to raise its full-year earnings guidance for the second time. This marks the second guidance increase in less than a month, exciting investors.

https://www.barrons.com/articles/cardinal-health-earnings-stock-price-360b636e?gaa_at=eafs&gaa_n=AWEtsqeeuxP34OngpqHIlTopxokkzovmCeU1Xwljbdn5fC4Xn1rRrNdB5_y_&gaa_ts=6984c7c7&gaa_sig=RJpiGvE5qjdJvG6rdiuLtR6LJ6xcTQG48UR4NHBHX1sMKYWwacUJFuptUvWEyPqXa--7SsV30Ui9ASCL0UUd0Q%3D%3D

Cardinal Health Smashes 52-Week High After Strong Quarter

Cardinal Health (NYSE:CAH) reported stronger-than-expected second-quarter results, with adjusted earnings of $2.63 per share and sales increasing 19% year-over-year to $65.63 billion. Bolstered by strong performance in its Pharmaceutical and Specialty Solutions segment, the company raised its fiscal year 2026 adjusted earnings per share guidance to $10.15-$10.35, leading its stock to a new 52-week high.

https://www.benzinga.com/markets/earnings/26/02/50415504/cardinal-health-smashes-52-week-high-after-strong-quarter

Trending Today

Bittensor ($TAO) Crypto Forecast: Down 5.2% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.2% Today

Under Armour Inc. Class A ($UAA) Stock Forecast: Up 5.0% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Up 5.2% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 5.8% Today

Unity Software ($U) Stock Forecast: Up 6.5% Today

Amphenol Corporation ($APH) Stock Forecast: Up 5.4% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

MicroStrategy ($MSTR) Stock Forecast: Up 8.6% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.0% Today

Cardinal Health Inc. Price History

05.00.2026 - CAH Stock was up 1.0%

• The strategic shift towards specialty pharmaceutical distribution and healthcare services by Cardinal Health is positively impacting its growth trajectory.
• The overall bullish sentiment in the pharmaceutical industry, as evidenced by the projected growth of the Palliative Care Market, is likely contributing to CAH's upward movement.
• Analysts lowering price targets for competitors like Cencora (COR) while maintaining a Neutral rating may be diverting investor attention towards Cardinal Health, driving its stock price higher.
• The recognition of Cardinal Health as a stable long-term investment due to its essential role in the healthcare supply chain and consistent demand for medications is attracting investors seeking steady growth opportunities.

02.11.2025 - CAH Stock was down 3.0%

• The bearish movement in Cardinal Health's stock today could be attributed to various factors:
• Despite the company's increased operating earnings, the recent revenue dip might have raised concerns among investors about its growth prospects.
• The acquisition announcement and year-end results reporting might have not met market expectations, leading to a negative sentiment towards the stock.
• The overall market sentiment towards healthcare stocks or specific developments within the healthcare sector could have influenced the bearish movement in CAH's stock price.
• Investors might be reevaluating Cardinal Health's financial stability and growth potential in comparison to other highlighted stocks with strong interest coverage ratios.
• The focus on financial metrics like the Price-to-Earnings ratio and valuation scores in discussions about other companies could have also shifted investor attention away from Cardinal Health, impacting its stock performance negatively.

13.00.2026 - CAH Stock was up 5.2%

• Following an upward trend, Cardinal Health's stock witnessed a surge subsequent to the company's revision of its fiscal-year guidance and its forecast of specialty revenue surpassing $50 billion for 2026.
• The optimistic projections for 2026, fueled by successful strategic moves like alterations in Medicare Drug Prices and alliances with Publix Super Markets, played a significant role in driving the stock's upward trajectory.
• Launches such as the ContinuCare™ Pathway program for diabetes supply management, coupled with strong performance across operational sectors, underscored the company's substantial strategic advancement.
• In essence, Cardinal Health's favorable forecasts and strategic endeavors have bolstered investors' confidence, thereby propelling the bullish trend in the stock market.

08.00.2026 - CAH Stock was down 3.0%

• The recent decline in CAH stock price could be linked to profit-taking by investors following a previous increase in value.
• Although Cardinal Health delivered impressive Q3 earnings that exceeded analyst expectations, market sentiment or profit-related concerns may have driven the stock lower.
• An increased investment by Robeco Institutional Asset Management B.V. initially inspired confidence in the stock, but prevailing market conditions may have overshadowed this development.
• Investor focus on the strong performance and growth potential of McKesson in the healthcare sector may have diverted attention from Cardinal Health, impacting its stock performance unfavorably.

05.01.2026 - CAH Stock was up 7.7%

• CAH surpassed analyst projections in its second-quarter earnings, leading to a rise in its stock value.
• The company adjusted its full-year earnings forecast upward for the second time, showing strong confidence in its future business performance.
• The robust results and achievement of a new 52-week high were driven by the strong performance in its Pharmaceutical and Specialty Solutions division.
• Investor sentiment towards CAH is optimistic, as analysts hold a consensus "Strong Buy" rating with potential for increased gains, reflecting confidence in the company's future growth.

05.01.2026 - CAH Stock was up 7.3%

• Today, Cardinal Health (CAH) witnessed a notable uptrend following the announcement of exceptional Q4 CY2025 results that outperformed market predictions.
• The company's strong financial showing was fueled by a substantial increase in revenue, surpassing analyst forecasts by a significant margin.
• Cardinal Health adjusted its full-year EPS guidance upwards, indicating optimism in its strategic efforts and the strong industry momentum in healthcare distribution.
• The upsurge in demand for specialty drugs and the company's foray into high-profit markets were key drivers in the positive outlook and the heightened profitability projections, further instilling investor confidence in Cardinal Health's future prospects.

05.01.2026 - CAH Stock was up 9.4%

• Cardinal Health's robust growth momentum, driven by strong utilization and successful acquisitions, has led to an impressive earnings report that surpassed analyst expectations.
• The company's consistent guidance hikes and increased fiscal-year earnings guidance have instilled confidence in investors, resulting in a surge in the stock price.
• Cardinal Health's focus on strategic initiatives and solid financial performance, including a significant increase in sales and adjusted earnings, has propelled the stock to reach a new 52-week high.
• The positive market sentiment towards Cardinal Health is further fueled by the CEO's explanation of the factors contributing to the company's success, reinforcing investor optimism in the stock's future prospects.

03.09.2025 - CAH Stock was down 3.7%

• Cardinal Health (CAH) may have faced a downward trend due to its underperformance relative to other medical stocks like Arcutis Biotherapeutics (ARQT).
• The subdued performance of CAH in the healthcare industry this year might be linked to the market's negative movement.
• Investors could be turning their attention towards more promising opportunities in the medical field, resulting in a sell-off of CAH shares.
• Contrasting with ARQT's strong showing could have revealed weaknesses in CAH's finances or growth prospects, prompting investors to review their positions and contributing to the bearish trend.

04.01.2026 - CAH Stock was down 5.0%

• Cardinal Health revised its FY25 earnings forecast upwards, anticipating notable growth in EPS over the next three years, which should typically have a positive effect on the stock.
• Allianz Asset Management GmbH decreased its ownership in Cardinal Health by 30%, potentially indicating investor uncertainty or profit-taking, which could have contributed to the recent market decline.
• Despite the encouraging earnings forecast and solid segment performance, the market's response towards Cardinal Health appears to have been more influenced by the significant reduction in ownership by a major investor, leading to the recent downturn.
• Various factors such as the overall healthcare sector's performance and general market trends may have also impacted the recent bearish movement of Cardinal Health's stock.

30.09.2025 - CAH Stock was up 17.6%

• Cardinal Health (CAH) saw a solid uptrend today, with its stock price rising by +1.72%.
• The positive market sentiment towards CAH is driven by expectations of robust Q1 earnings, especially in its Pharmaceutical and Specialty units.
• CAH has consistently outperformed the market over the past 5 years, with an average annual return of 27.8%, attracting investors seeking stable returns in the healthcare sector.
• The favorable expectations for CAH's financial performance and its strong position in the healthcare industry have fueled the uptick in its stock price today.

30.09.2025 - CAH Stock was up 17.4%

• Cardinal Health (CAH) experienced a strong bullish movement today, with its stock price increasing by +1.72%.
• The positive market movement can be attributed to the expectation of double-digit revenue growth in Q1 FY26, primarily driven by the Pharmaceutical and Specialty units.
• Additionally, the company's consistent outperformance in the market over the past 5 years, with an average annual return of 27.8%, has likely contributed to investor confidence and buying interest in CAH shares.
• Overall, the market seems optimistic about Cardinal Health's future prospects, supported by strong financial performance and growth potential in key business segments.

30.09.2025 - CAH Stock was up 13.0%

• The stock of Cardinal Health saw a notable increase following the positive announcement of its first-quarter 2026 earnings. Adjusted earnings outperformed expectations, and sales witnessed a substantial year-over-year growth.
• Cardinal Health's successful performance in Q1 and the upgraded 2026 EPS forecast point towards a widespread expansion and growing profitability across all sectors, fostering investor confidence.
• Investor optimism towards Cardinal Health has been influenced by its consistent market outperformance in the last 5 years, indicating attractive returns for stakeholders.
• Anticipated double-digit revenue growth in the first quarter of fiscal year 2026, especially in the Pharmaceutical and Specialty units, has further heightened investor confidence in the company's future prospects, encouraging a bullish trend in the stock price.